Arcus Biosciences (RCUS) concentration risks

The company carries a dense, multi-layered concentration profile that stacks pipeline, counterparty, and supply dependencies at uniformly high disclosed size. The pipeline is anchored by casdatifan, for which the company holds all commercial rights and which is in a Phase 3 clinical trial — making it a mixed-character exposure where success would be transformational but a clinical setback would eliminate the program entirely from the commercial profile. Layered on that is a high-share counterparty dependency on Gilead: the company expects to depend on this collaboration for the research, development, manufacture, and commercialization of certain investigational products. With Gilead embedded across multiple functions — not just funding but also manufacturing and commercial execution — the relationship is deeply load-bearing, and any material change in Gilead's strategic priorities or its terms under the collaboration would have broad consequences. On the manufacturing side, WuXi Biologics is the designated exclusive manufacturer of zimberelimab drug substance for clinical and commercial supply, and the company sources drug product for investigational compounds from single-source third-party contract manufacturers. These two supply dependencies are both high-share by disclosed size, compounding the counterparty risk: disruptions at WuXi Biologics or at any single-source drug product manufacturer could delay or interrupt supply for multiple programs simultaneously. In aggregate, the profile reflects a company whose operational and commercial continuity is tightly linked to a small set of named and unnamed external parties across pipeline, partnerships, and production.

For the engine’s reasoning on RCUS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.